NeuroPace 8-K Details Executive Comp/Officer Changes
Ticker: NPCE · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1528287
| Field | Detail |
|---|---|
| Company | Neuropace Inc (NPCE) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $32,226 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, corporate-governance
TL;DR
**NeuroPace just filed an 8-K about executive changes, watch for details on compensation.**
AI Summary
NeuroPace Inc. filed an 8-K on February 7, 2024, reporting an event that occurred on February 1, 2024, related to changes in its executive compensation or officer arrangements. This filing, under Item 5.02, indicates potential shifts in how the company compensates its leadership, which could impact future financial performance and investor confidence. For shareholders, understanding these changes is crucial as executive compensation directly affects the company's bottom line and can signal strategic shifts in management's priorities.
Why It Matters
Changes in executive compensation or officer roles can signal strategic shifts, impact operational stability, and affect the company's financial health, directly influencing stock valuation.
Risk Assessment
Risk Level: medium — Changes in executive compensation or officer roles can introduce uncertainty regarding leadership stability and future strategic direction, posing a medium risk.
Analyst Insight
Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and compensation arrangements, as these will provide clarity on potential impacts to the company's strategy and financial outlook.
Key Players & Entities
- NeuroPace Inc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of the earliest event reported
- February 7, 2024 (date) — date the 8-K was filed
- Item 5.02 (other) — the specific item under which the event is reported, related to departure/election of officers and compensatory arrangements
Forward-Looking Statements
- NeuroPace will announce specific details regarding executive compensation or officer changes within the next quarter. (NeuroPace Inc.) — medium confidence, target: Q2 2024
FAQ
What specific event did NeuroPace Inc. report in this 8-K filing?
NeuroPace Inc. reported an event under Item 5.02, which covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
When did the earliest event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on February 1, 2024.
What is the filing date of this 8-K for NeuroPace Inc.?
The filing date of this 8-K for NeuroPace Inc. is February 7, 2024.
What is NeuroPace Inc.'s trading symbol and on which exchange is its common stock registered?
NeuroPace Inc.'s common stock trades under the symbol NPCE on the Nasdaq Global Market.
What is the business address of NeuroPace Inc. as stated in the filing?
The business address of NeuroPace Inc. is 455 N. Bernardo Avenue, Mountain View, CA 94043.
Filing Stats: 770 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-02-07 16:43:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share NPCE Nasdaq Glo
- $32,226 — one-time cash payment in the amount of $32,226. The severance payments and the one-tim
Filing Documents
- d652550d8k.htm (8-K) — 25KB
- 0001193125-24-026756.txt ( ) — 144KB
- npce-20240201.xsd (EX-101.SCH) — 3KB
- npce-20240201_lab.xml (EX-101.LAB) — 18KB
- npce-20240201_pre.xml (EX-101.PRE) — 11KB
- d652550d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NeuroPace, Inc. Dated: February 7, 2024 By: /s/ Rebecca Kuhn Rebecca Kuhn Chief Financial Officer